ArticleKidney medicine2025
Taurolidine-induced Severe Anaphylaxis.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on Horvath et al: Presumable Taurolidine-Associated Anaphylaxis.Kidney medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taurolidine-based catheter lock solutions are widely used for central venous catheters. Although minor infusion-related symptoms and allergic reactions have been documented, no systemic effects or severe cases of anaphylaxis have been observed. Here, we detail a case of taurolidine-induced life-threatening anaphylaxis. We report the case of a 59-year-old man who had a severe anaphylactic reaction to taurolidine following accidental intravenous infusion, which required treatment in the intensive care unit. Anaphylactic shock, which was resistant to conventional treatment with epinephrine, required additional management with norepinephrine and vasopressin. After the resolution of the anaphylactic episode, the patient was discharged from the intensive care unit. An outpatient allergy work-up using a skin prick test was performed, which confirmed a suspected allergy to taurolidine. In conclusion, taurolidine induced a severe, prolonged anaphylactic shock that did not respond to conventional treatment with intravenous and inhaled epinephrine, antihistamines, glucocorticoids, or continuous norepinephrine infusion. New treatment strategies for refractory anaphylactic shock are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.